Clinical trial results
Actor portrayals.
Discover what's possible with your RYBREVANT FASPRO™–based or RYBREVANT®-based treatment:
More time without cancer
getting worse
The amount of time that people taking RYBREVANT® + chemotherapy lived without their cancer growing or spreading was 6.3 months vs 4.2 months for people taking just chemotherapy.
Make tumors shrink or
disappear†
52% of people taking RYBREVANT® + chemotherapy had their tumors shrink vs 29% of people taking just chemotherapy.
Tumors disappeared in 1% of people taking RYBREVANT® + chemotherapy, and in 0% of people taking just chemotherapy.
What do these results mean if you've been prescribed RYBREVANT FASPRO™ + chemotherapy instead of RYBREVANT® + chemotherapy?
Whether you get your medicine as a RYBREVANT FASPRO™ injection or RYBREVANT® infusion, both ways are similarly helpful in treating your cancer.
Where did these results come from?
RYBREVANT® + chemotherapy was compared with just chemotherapy in a clinical trial. A group of 394 people received either RYBREVANT® + chemotherapy or just chemotherapy as their second treatment after the current standard of care (osimertinib) for advanced NSCLC with exon 19 deletions or exon 21 L858R EGFR substitution mutations.
*Exon 19 deletion or exon 21 L858R substitution mutations.
†When tumors shrink, they are measurably smaller but they can still be seen on scans by your doctor. And even if a tumor disappears, it does not necessarily mean the cancer has been cured.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.
About side effects
Learn more about the side effects that you may experience during treatment with RYBREVANT FASPRO™ + chemotherapy or RYBREVANT® + chemotherapy.
Savings & support
Once prescribed RYBREVANT FASPRO™ or RYBREVANT®, connect with a Care Navigator for your support needs.